관해유도 화학요법을 받는 급성 백혈병 환자에서 발생한 감염증에서 Imipenem 단독요법과 Ceftizoxime ＋ Amikacin 병용요법의 효과 및 안전성에 관한 전향적 비교 연구 = A Prospective Randomized Trial Comparing Imipenem Alone with Ceftizoxime and Amikacin in Febrile Leukemic Patients Undergoing Induction Chemotherapy

다국어 초록 (Multilingual Abstract)

A total of 40 febrile granulocytopenic patients with acute leukemia were randomized to receive imipenem-cilastatin or ceftizoxime plus amikacin as initial empirical therapy to compare the efficacy and safety of imipenem monotherapy with that of ceftizoxime/amikacin combination therapy. 21 patients were randomized to the imipenem monotherapy, while 19 patients to the ceftizoxime/amikacin combination therapy. On 72 hour assessment success rates accordings to NCI criteria were 100% in both groups, success rates according to IHS (Immunocompremised Host Society) criteria were 55.0% in imipenem group and 66.7% in ceftizoxime/amikacin group. On overall assessment success rates according to NCI criteria were 90.0% in imipenem group and 94.7% in combination group, success rates according to IHS criteria were 50% in both groups. There was no statistical difference in success rate between two groups. Hepatotoxicity was the most common side effect in both groups(imipenem 15.0% vs. ceftizoxime/amikacin 15.8%). There was no CNS tixicity in both groups. Nausea and vomiting occurred in 9.5% of imipenem recipients, and 1 patients was unable to complete therapy due to intolerance. In summary, imipemem monotherapy was effective and safe empirical antibiotic therapy as compared with ceftizoxime/amikacin combination therapy.